A new study by researchers from the American Cancer Society (ACS) finds that approximately 137 million adults in America (56 percent) reported having medical financial hardship in the past year. Highlights of the report include:
On April 23, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule that would update Medicare payment policies for hospitals under the Inpatient Prospective Payment System (IPPS) and the Long-Term Care Hospital (LTCH) Prospective Payment System (PPS) for fiscal year (FY) 2020.
In the IPPS proposed rule, the agency proposes to:
Read the agency fact sheet.
Access the proposed rule.
The National Institutes of Health (NIH)/National Cancer Institute (NCI) have announced a funding opportunity RFA-CA-19-035, titled "Optimizing the Management and Outcomes for Cancer Survivors Transitioning to Follow-Up Care (RO1 Clinical Trial Required)"
The Funding Opportunity Announcement (FOA) solicits applications that develop and test models of care for adult survivors of cancer who are transitioning from active treatment to follow-up care. Through this FOA, the NCI intends to support multi-level interventions that enhance communication, collaboration, and coordination among oncology and non-oncology providers to improve cancer survivor outcomes.
Interventions that focus on the needs of racial/ethnic minority or medically underserved adult survivors and/or those receiving care in community settings (including, but not limited to, community-based cancer centers) are not required but strongly encouraged. NCI seeks to fund applications that represent a broad spectrum of cancer survivors (e.g., variability in demographics, cancer type, clinical characteristics) and care delivery settings (e.g., community settings, integrated healthcare settings).
Open Date (Earliest Submission Date): May 28, 2019
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Date(s): June 28, 2019, by 5:00 PM local time of applicant organization.
DATE FOR PRE-APPLICATION WEBINAR for RFA-CA-19-035
May 3, 2019
1:00 PM - 2:00 PM (ET)
On Friday, May 3, 2019 from 1:00 - 2:00 PM (ET), NCI will hold a pre-application webinar for RFA-CA-19-035 entitled "Optimizing the Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care (R01 Clinical Trial Required)."
NCI staff members involved in this FOA will provide orientation and technical assistance to potential applicants to the above-referenced FOA by explaining the goals and objectives for the proposed FOA and answer questions from webinar attendees. Potential applicants are encouraged to submit their questions to NCIHDRP@mail.nih.gov by 12 pm ET on May 1, 2019.
To join the webinar, pre-registration is required through Webex. Specific webinar information will be provided upon registration.
The U.S. Food and Drug Administration issued a proposed rule on March 27 that would make amendments to the regulations issued under the Mammography Quality Standards Act (MQSA) of 1992 that seek to improve the quality of mammography services. The proposed rule would expand the information mammography facilities are required to provide to patients and healthcare professionals to allow for more informed medical decision-making, the agency said in a statement. It also modernizes mammography quality stands and strengthens the FDA’s ability to enforce regulations that apply to the safety and quality of mammography services.
Under the proposed rule, breast density information would be added to the mammography lay summary letter provided to patients and to the medical report provided to their referring healthcare professionals.
The amendments would also expand the information provided to healthcare professionals by proposing to codify three additional categories for the assessments of mammograms, including adding an important category titled “known biopsy proven malignancy,” which would help identify for healthcare professionals those cases where cancer being mammographically evaluated for therapy are already known and identified.
Under the proposed regulations, both healthcare professionals and patients would receive in their reports and lay summary letters more detailed identifying information about the mammography facility to aid in post-exam communications, the agency said.
The proposed rule will be open for public comment for 90 days after publication.
Read the FDA press release.
View the proposed rule.